AIDOT (CEO Jung Jae-hoon) announced that it participated—through its sole domestic partner, the Korea Phil Medical Foundation (KCL) / Korea Clinical Medicine Research Institute—in the 15th Spring Academic Conference of the (Direct Election System) Korean Association of Obstetricians and Gynecologists, held on April 9 at the Swiss Grand Hotel Convention Center in Seoul.

At the event, the company showcased Cerviray AI, its AI-based remote reading system for cervical cancer screening.

Attendees visited the booth to learn how AIDOT’s innovative AI technology is used for early cervical cancer screening. Because a large portion of participants were OB-GYN specialists, the company said they were able to readily understand the potential benefits that Cerviray’s fast and accurate results could bring to real-world screening workflows.

Cerviray not only became Korea’s first to obtain MFDS approval (Class III) as an AI-based medical device, but has also proven its excellence by completing commercialization both in Korea and overseas with its advanced proprietary AI algorithm. AIDOT stated that this market validation is helping it further differentiate itself and widen the gap versus late entrants.

CEO Jung Jae-hoon said, “As Cerviray has been commercialized in many overseas countries, it continues to improve day by day by incorporating and learning from additional meaningful clinical information,” adding, “The era of discussing AI solely based on the volume of data is already over.” He emphasized Cerviray’s high accuracy and stated that as AIDOT expands across diverse countries worldwide, it will also pursue aggressive marketing in Korea to promote women’s health domestically as well as globally, and further increase the gap with late entrants.

Published: April 18, 2023 / Korea Economic TV / Reporter Park Jun-sik